Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636792 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 2
- Study locations
NCT00636792: Completed Phase 2 study of Follicular Lymphoma, sponsored by Millennium Pharmaceuticals.
NCT00636792 is a Phase 2 study of Follicular Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 73 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (46% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00636792, a Phase 2 study of Follicular Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
Primary Outcome
Response is assessed by investigator according to International Working Group (IWG) criteria. Complete response requires disappearance of all evidence of disease.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Bendamustine
- DRUG VELCADE
Study Locations (2)
District of Columbia
- Georgetown University Medical Center - Washington D.C.
North Dakota
- MidDakota Clinic - Cancer Treatment and Research Center - Bismarck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00636792 record still lists
NCT00636792 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.
NCT00636792 reports a single indexed study location in District of Columbia, North Dakota.
Frequently Asked Questions
What is clinical trial NCT00636792 about?
NCT00636792 is a clinical study titled "A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma". This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refract...
What is the current status of trial NCT00636792?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2008-02. Estimated completion is 2010-05.
What conditions does trial NCT00636792 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT00636792?
The interventions under investigation include: Rituximab (DRUG), Bendamustine (DRUG), VELCADE (DRUG).
Who is sponsoring clinical trial NCT00636792?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00636792 being conducted?
This trial has 2 study locations across District of Columbia, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00636792's enrollment target sits among peer trials
73 38th of 89 higher than 52 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia